Abstract

The Cancer Cell Signaling (SIG) program seeks to stimulate and facilitate fundamental research in mechanisms of cell signaling. SIG does this through new faculty recruitment, and promoting program interactions, collaborations, and information sharing. Co-leaders of the program David L. Brautigan and Kimberly A. Kelly decide on program membership status in consultation with senior leadership, and act as advisors for faculty and mentors for fellows and students by encouraging team-based research projects, and participating in the weekly Cancer Center seminar series, student journal clubs, and programmatic research conferences. SIG is comprised of 25 members from 15 different basic science and clinical departments in the School of Medicine and School of Engineering and Applied Science, and 2 associate members. The high quality science by SIG has resulted in over 318 publications over the past 5 years, with 43% inter- programmatic and 10% intra-programmatic co-authorships. Total extramural funding for the Program exceeds $8.8M, including over $3.9 million from the National Cancer Institute (NCI) and $3.8M from other NIH institutes. Members of SIG are a valuable resource and highly collaborative, supporting activities throughout the Cancer Center, as one of the cornerstones of the UVA Cancer Center research enterprise.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-26
Application #
9209276
Study Section
Special Emphasis Panel (NCI (E3)-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
26
Fiscal Year
2017
Total Cost
$27,633
Indirect Cost
$10,144

  Institution

Name
University of Virginia
Department
Type
Domestic Higher Education
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904

  Publications

Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255

Showing the most recent 10 out of 539 publications